J 2021

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis

HYZA, M., P. SILHAN, E. CESKOVA, T. SKRONT, I. KACIROVA et. al.

Základní údaje

Originální název

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis

Autoři

HYZA, M., P. SILHAN, E. CESKOVA, T. SKRONT, I. KACIROVA, R. URINOVSKA a M. GRUNDMANN

Vydání

Neuropsychiatric Disease and Treatment, New Zealand, Dove Medical Press, 2021, 1176-6328

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.154 v roce 2013

UT WoS

000641063300001

Klíčová slova anglicky

therapeutic drug monitoring; antipsychotics; psychotic disorders; schizophrenia
Změněno: 7. 12. 2021 13:00, Bc. Hana Vladíková, BBA

Anotace

V originále

Purpose: Antipsychotic efficacy in schizophrenia depends on its availability in the body. Although therapeutic outcomes remain still far from satisfactory, therapeutic drug monitoring not a common part of clinical practice during treatment with long-acting injectable antipsychotics (LAI AP). The real effectiveness of LAI AP is thus uncertain. Patients and Methods: We made a retrospective evaluation of plasma levels of LAI AP. Collection of blood samples was performed just before the drug application and one week later. Forty patients with a stabilized clinical condition and steady-state plasma levels were included. Results: In the observed cohort of patients, flupentixol decanoate (n = 23) was the most often used drug, followed by fluphenazine decanoate (n = 7), haloperidol decanoate (n = 5), paliperidone palmitate (n = 3), and risperidone microspheres (n = 2). Just 5 of 40 patients were treated with a monotherapy. In the period before the application, 60% of the patients did not reach the therapeutic reference range (TRR) and 20% of the patients had an undetectable plasma level. At the time of collection of the second blood samples performed after 7 days, 24% of the patients were under the TRR. Conclusion: We have found a surprisingly high incidence of plasma levels under the TRR patients treated with LAI AP. Notwithstanding individual variability in pharmacokinetics, seems that LAI AP may be underdosed in usual clinical practice.

Návaznosti

90128, velká výzkumná infrastruktura
Název: CZECRIN III